ARC Epidemiology Unit, Manchester Academic Health Sciences Centre, The University of Manchester Stopford Building, Oxford Road, Manchester M13 9PT, UK.
Rheum Dis Clin North Am. 2010 Feb;36(1):81-97, viii. doi: 10.1016/j.rdc.2009.12.004.
The metabolic syndrome (MetS) is a recently defined clustering of cardiovascular risk factors associated with increased insulin resistance and a high risk of developing type II diabetes mellitus. Systemic lupus erythematosus (SLE) is associated with an increased prevalence of the MetS and patients also show evidence of increased insulin resistance. Controversy remains, however, regarding the precise definition of the MetS and its exact role in predicting long-term coronary heart disease risk both in SLE and in the general population. The major benefit of identifying the MetS in patients with SLE is likely to be from highlighting patients for focused lifestyle interventions and helping to guide individualized therapeutic regimes that take into account cardiovascular risk.
代谢综合征（MetS）是一种新近定义的心血管危险因素聚类，与胰岛素抵抗增加和 II 型糖尿病发病风险增加相关。系统性红斑狼疮（SLE）与 MetS 的患病率增加相关，患者也表现出胰岛素抵抗增加的证据。然而，关于 MetS 的精确定义及其在预测 SLE 和一般人群中的长期冠心病风险方面的确切作用仍存在争议。在 SLE 患者中确定 MetS 的主要益处可能是突出强调患者需要进行有针对性的生活方式干预，并有助于指导个体化的治疗方案，考虑心血管风险。
